Tyrosine Kinase Inhibitor

Triple Therapy for CLL/SLL

Philadelphia, PA

Phase 1

Waitlist Available

Led By Catherine Lai

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective

Previously treated, pathologically confirmed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that requires as per the National Cancer Institute (NCI) Working Group Guidelines for the treatment of CLL

Must not have

Currently active, clinically significant hepatic impairment (>= moderate hepatic impairment according to the NCI/Child Pugh classification)

Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatment

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 10 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is studying the side effects and best dose of lenalidomide when given with ibrutinib and rituximab to treat patients with CLL or SLL that has come back, is refractory, has spread, or cannot be removed by surgery.

See full description

Who is the study for?

This trial is for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that's returned, spread, or can't be surgically removed. Eligible participants must not have severe allergies to the drugs being tested, no recent heart issues or strokes, and should not be pregnant. They need functioning major organs and cannot have used certain treatments recently.Check my eligibility

What is being tested?

The trial tests a combination of lenalidomide with ibrutinib and rituximab to see how well they work together against cancer cells. It's in phase I to determine side effects and the best dose. The study includes collecting biospecimens, bone marrow biopsies, imaging tests like CT scans and MRIs.See study design

What are the potential side effects?

Possible side effects include immune system reactions leading to inflammation in various organs, fatigue, blood disorders such as anemia or clotting problems, increased risk of infections due to lowered immunity from rituximab therapy.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer is advanced, cannot be surgically removed, and standard treatments are not effective.

show original

Select...

I have been treated for CLL or SLL and need further treatment.

show original

Select...

I haven't had serious heart problems or heart failure in the last 6 months.

show original

Select...

My cancer can be measured by tests or scans.

show original

Select...

I haven't had any treatment for CLL or SLL, including chemo, immunotherapy, or radiation, in the last 4 weeks.

show original

Select...

I haven't had radioimmunotherapy in the last year.

show original

Select...

I have no allergies to ibrutinib, lenalidomide, rituximab, or similar drugs.

show original

Select...

I have never had a stem cell transplant from another person.

show original

Select...

My cancer is advanced, cannot be surgically removed, and standard treatments have failed. I have CLL or SLL that meets specific diagnostic criteria but haven't had Richter's transformation.

show original

Select...

I have been diagnosed with CLL based on specific blood markers.

show original

Select...

I can do all or most of my daily activities without help.

show original

Select...

I have HIV but no hepatitis, my CD4+ count is 400 or higher, and my HIV isn't resistant.

show original

Select...

My neurological condition is stable without needing steroids or seizure medications.

show original

Select...

I do not have a bleeding disorder that requires regular blood transfusions.

show original

Select...

I do not have a history of seizures that are hard to control.

show original

Select...

I agree to use two forms of birth control or practice abstinence during the study.

show original

Select...

I agree to use a condom during sex, even though I've had a vasectomy.

show original

Select...

I am a woman capable of becoming pregnant.

show original

Select...

I don't have any serious illnesses that are not under control.

show original

Select...

I haven't taken any corticosteroids in the last 2 weeks.

show original

Select...

I can swallow pills and do not have major issues with my gut that affect absorption.

show original

Select...

I have never taken Bruton's tyrosine kinase inhibitor.

show original

Select...

I have fluid buildup in my abdomen.

show original

Select...

I have lymphangitis in my skin or lungs.

show original

Select...

I do not have active or uncontrolled autoimmune blood disorders.

show original

Select...

My kidney function, measured by creatinine clearance, is adequate.

show original

Select...

I am not taking warfarin or similar blood thinners.

show original

Select...

I have fluid around my lungs or heart.

show original

Select...

I do not have an autoimmune disorder needing immunosuppressants.

show original

Select...

My cancer can be seen or measured on a scan or physical exam.

show original

Select...

My tumor is larger than 1 cm.

show original

Select...

I am not currently on any approved cancer treatments or experimental drugs.

show original

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I do not have moderate or severe liver problems.

show original

Select...

I haven't had chemotherapy in the last 3 weeks or monoclonal antibody treatment in the last 6 weeks.

show original

Select...

I have been treated with a BTK inhibitor before.

show original

Select...

I need regular blood transfusions due to low platelet counts.

show original

Select...

I do not take daily corticosteroids or take less than 20 mg of prednisone equivalent.

show original

Select...

I have serious heart problems or had a recent heart attack.

show original

Select...

I have a bleeding disorder like von Willebrand's disease or hemophilia.

show original

Select...

I am willing and able to follow all study requirements.

show original

Select...

I have not had major surgery in the last 4 weeks.

show original

Select...

I cannot swallow pills or have serious digestive system issues.

show original

Select...

I haven't taken strong CYP3A inhibitors in the last 7 days.

show original

Select...

I have an autoimmune condition affecting my blood cells and it's not under control.

show original

Select...

I do not have any severe illnesses that could interfere with the study.

show original

Select...

I have brain metastases.

show original

Select...

I am HIV-positive but my CD4 count is within normal range.

show original

Select...

I am currently taking warfarin or similar blood thinners.

show original

Select...

I haven't taken any immune-suppressing drugs other than steroids in the last 28 days.

show original

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 10 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 10 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Recommended phase II dose of lenalidomide and ibrutinib with rituximab based on the maximum tolerated dose and the assessment of any clinically relevant toxicity

Secondary study objectives

Complete response rates

Incidence of adverse events

Overall response rate

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (lenalidomide, ibrutinib, rituximab)Experimental Treatment8 Interventions

Patients receive rituximab IV on day 1 (up to 6 cycles), lenalidomide PO QD on days 1-21 (up to 12 cycles), and ibrutinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo ECG on screening and CT scan or MRI, bone marrow biopsy and blood sample collection throughout the study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Electrocardiogram

2014

Completed Phase 2

~3060

Biospecimen Collection

2004

Completed Phase 3

~1810